Welcome to our dedicated page for PLUS THERAPEUTICS news (Ticker: PSTV), a resource for investors and traders seeking the latest updates and insights on PLUS THERAPEUTICS stock.
Plus Therapeutics, Inc. (symbol: PSTV) is a cutting-edge clinical-stage pharmaceutical company based in Austin, Texas. Founded in 1996 and initially known as Cytori Therapeutics, Inc., the company rebranded to Plus Therapeutics in July 2019 to better reflect its mission and evolving focus. Specializing in the discovery, development, and manufacture of innovative treatments for cancer and other debilitating diseases, Plus Therapeutics aims to bring new hope to patients through cutting-edge medical solutions.
The company's lead product candidate is DocePLUS, a protein-stabilized, pegylated liposomal formulation of docetaxel specifically designed for the treatment of small cell lung cancer. Additionally, Plus Therapeutics is developing DoxoPLUS, a generic pegylated liposomal encapsulated doxorubicin aimed at treating breast and ovarian cancer, multiple myeloma, and Kaposi's sarcoma.
In a significant partnership, Plus Therapeutics has entered into a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. This collaboration aims to propel the company further into the forefront of cancer treatment research.
One of the company's groundbreaking developments is the novel injectable radiotherapy called Rhenium (186Re) obisbemeda. This treatment is specifically formulated to deliver targeted high-dose radiation in Central Nervous System (CNS) tumors, optimizing patient outcomes while minimizing off-target risks. The product's efficacy and safety are being evaluated for recurrent glioblastoma and leptomeningeal metastases in the ReSPECT-GBM and ReSPECT-LM clinical trials. These trials are supported by grants from the National Cancer Institute (NCI) and the Cancer Prevention & Research Institute of Texas (CPRIT), totaling millions in funding.
Financially, Plus Therapeutics recently secured $6.5 million in upfront gross proceeds, with the potential to receive up to an additional $11.5 million through potential warrant exercise, amounting to approximately $18 million in total gross proceeds. These funds will be essential in advancing the company’s robust pipeline and bringing innovative treatments to market.
Investors and stakeholders can stay informed of the latest developments and financial updates by reaching out to key contacts such as Corey Davis, Ph.D. of LifeSci Advisors, and Charles Y. Huang, MBA, Director of Capital Markets and Investor Relations.
Plus Therapeutics (Nasdaq: PSTV) announced its participation in the 22nd H. C. Wainwright Annual Global Investment Conference from September 14-16, 2020. The Company is scheduled to present on September 15 at 4:00 p.m. ET, with one-on-one meetings available during the event. The presentation will be live-streamed and accessible for later viewing. Plus Therapeutics focuses on developing innovative drug delivery systems targeting rare cancers, utilizing a unique nanotechnology platform to enhance treatment safety and efficacy. More details can be found on their corporate website.
Plus Therapeutics (Nasdaq: PSTV) announced its invitation to present at the 9th Annual Gateway Conference, scheduled for September 9-10, 2020. The management will present on September 10 at 3:30 p.m. ET. A live webcast of the presentation will be available for replay. Interested parties can schedule one-on-one meetings during the conference by contacting conference@gatewayir.com.
This conference connects compelling companies with top institutional investors, aimed at enhancing investor relations.
Plus Therapeutics, Inc. (PSTV) announced its participation in the LD 500 investor conference on September 4, 2020, at 10:20 AM ET. Dr. Marc Hedrick, the company's President and CEO, will present and engage in a Q&A session with investors. The conference occurs from September 1-4 and aims to provide a virtual platform for exposure to unique companies amid the COVID-19 pandemic. LD Micro's founder, Chris Lahiji, emphasizes accessibility for all participants. For more details, visit Plus Therapeutics' profile and register for the event.
Plus Therapeutics, Inc. (Nasdaq: PSTV) reported a Q2 2020 net loss of $1.8 million, or $0.45 per share, significantly reduced from a loss of $9.1 million, or $20.67 per share, in Q2 2019. The company ended the quarter with $9.3 million in cash. Key developments include ongoing clinical trials for Rhenium NanoLiposomes (RNL™) aimed at treating recurrent glioblastoma, with preliminary data expected soon. The firm plans to finalize its Phase 2 trial plan and seek Orphan Drug Designation while exploring partnerships for its oncology portfolio.
Plus Therapeutics (Nasdaq: PSTV) will release its Second Quarter Fiscal Year 2020 financial results after market close on August 10, 2020. A conference call at 5:00 PM ET will provide insights into the results and a business update. The company focuses on developing radiotherapeutics using its nanotechnology platform to target rare cancers. This technology enhances drug delivery and formulation for improved patient safety and convenience.
Plus Therapeutics (Nasdaq: PSTV) announced the successful completion of the fifth cohort of the ReSPECT Clinical Trial, evaluating Rhenium NanoLiposomes (RNL™) in adults with recurrent glioblastoma (GBM). The trial has expanded to a second site at UT Southwestern Medical Center, enrolling 15 patients across five cohorts, with six more planned. RNL aims to deliver radiation doses up to 25 times greater than conventional methods, with further developments anticipated including cohort 6, completion of enrollment, and potential orphan drug designations.
Plus Therapeutics (PSTV) announced its participation in the YAFO ACCESS CHINA - 2020 Summer Online Partnering Day, scheduled for July 30, 2020, at 10:00 p.m. EST. Dr. Marc Hedrick will lead the presentation and engage with investors during the session. Attendees can register for free tickets to join the live event or opt for a Video on Demand Ticket. A replay will be available on the company's website a week later for those unable to attend live. Plus Therapeutics specializes in developing radiotherapeutics targeting rare cancers using a unique nanotechnology platform.
On July 6, 2020, Plus Therapeutics, Inc. (PSTV) announced the approval of stock options for key executives. Dr. Gregory Stein was granted options for 40,000 shares at an exercise price of $2.11, and Andrew Sims received the same number at $2.23, both vesting over four years. This decision aligns with the company's 2015 New Employee Incentive Plan, which was recently amended to allow additional shares for inducement awards. Plus Therapeutics is focused on developing innovative cancer therapies.
Plus Therapeutics (PSTV) reported its Q1 2020 financial results with a net loss of $1.1 million, or $0.28 per share, showing improvement from a $2.5 million loss in Q1 2019. Operating cash usage decreased to $1.5 million compared to $3.3 million last year. The company has secured a licensing agreement for rare cancer therapies, including Rhenium-186-chelated NanoLiposome for glioblastoma, with potential milestone payments totaling $136.5 million. Plus Therapeutics ended the quarter with $16.1 million in cash and emphasizes ongoing clinical trials and pipeline expansion.
Plus Therapeutics (PSTV) announced a live webinar, led by Dr. Andrew Brenner, on a new radiotherapy for recurrent glioblastoma scheduled for May 17, 2020. This initiative is part of the Musella Foundation Webinar Series and aims to educate patients and raise awareness during Brain Tumor Awareness Month. Plus Therapeutics recently licensed a radiolabeled nanoliposome drug portfolio, with its lead asset, Rhenium NanoLiposome (RNL™), supported by a $3.7 million NIH/NCI grant. The platform focuses on delivering high-dose radiation directly to brain tumors via advanced delivery techniques.
FAQ
What is the current stock price of PLUS THERAPEUTICS (PSTV)?
What is the market cap of PLUS THERAPEUTICS (PSTV)?
What is Plus Therapeutics, Inc.?
What are the main products of Plus Therapeutics?
What is Rhenium (186Re) obisbemeda?
What partnerships does Plus Therapeutics have?
What recent financial achievements has Plus Therapeutics made?
Where is Plus Therapeutics headquartered?
What clinical trials is Plus Therapeutics involved in?
Who can investors contact for more information?
What was the former name of Plus Therapeutics?
When was Plus Therapeutics founded?
